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Abstract: In this report, a formula for estimating the prevalence ratio of a disease in a population
that is tested with imperfect tests is given. The formula is in terms of the fraction of positive test
results and test parameters, i.e., probability of true positives (sensitivity) and the probability of
true negatives (specificity). The motivation of this work arises in the context of the COVID-19
pandemic in which estimating the number of infected individuals depends on the sensitivity and
specificity of the tests. In this context, it is shown that approximating the prevalence ratio by
the ratio between the number of positive tests and the total number of tested individuals leads to
dramatically high estimation errors, and thus, unadapted public health policies. The relevance of
estimating the prevalence ratio using the formula presented in this work is that precision increases
with the number of tests. Two conclusions are drawn from this work. First, in order to ensure
that a reliable estimation is achieved with a finite number of tests, testing campaigns must be
implemented with tests for which the sum of the sensitivity and the specificity is sufficiently
different from one. Second, the key parameter for reducing the estimation error is the number of
tests. For large number of tests, as long as the sum of the sensitivity and specificity is different
from one, the exact values of these parameters have very little impact on the estimation error.
Key-words: SARS-CoV-2; Covid-19; Cross-Sectional Studies; Prevalence Ratio; Sensitivity and
Specificity; Molecular, Serological and Medical Imaging diagnostics; Number of Infections; False
Positive and False Negative Probabilities; Policy-Making and Testing Campaigns
Résumé : Ce rapport présente une formule mathématique pour estimer le nombre d’infections
SARS-CoV-2 dans une population donnée. La formule utilise les résultats et les paramètres
des tests, c’est-à-dire la probabilité de vrais positifs (sensibilité) et de vrais négatifs (spécificité).
Selon la sensibilité et la spécificité des tests, le nombre de résultats positifs peut être radicalement
différent du nombre d’individus infectés. Ainsi, le nombre final de résultats rendus positifs n’est
pas une source d’information fiable pour la prise de décision ou l’élaboration des directives.
Deux conclusions sont tirées de ce travail; afin de garantir l’obtention d’une estimation fiable,
des campagnes de tests doivent être mises en oeuvre avec des tests pour lesquels la somme de la
sensibilité et de la spécificité est significativement différente de un. De plus, il est prouvé qu’un
nombre important de tests conduit à une estimation plus précise du nombre d’infectés. Pour un
grand nombre de tests, tant que la somme de la sensibilité et de la spécificité n’est pas égale à
un, les valeurs exactes de ces paramètres ont très peu d’impact sur l’erreur d’estimation.
Mots-clés : Covid-19, SARS-CoV-2, sensibilité, spécificité, PCR, test virologique, test
sérologique, nombre d’infections, estimation, faux négatifs, faux positifs, analyse de données,
élaboration de politiques, campagnes de tests.
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1 Introduction
In the absence of a vaccination or effective medical treatment against the SARS-CoV-2, the global
population must cohabitate with the virus. For succeeding in this task, different strategies to slow
down the outbreak can be implemented, for example, encouraging social distancing, isolation of
infected individuals, mobility restrictions, lockdowns, and contact tracing. The main objective is
to guarantee that the number of infected individuals that develop critical forms of symptoms does
not exceed the capacity of local health care systems. Nonetheless, most of the strategies to slow
down the outbreak induce dramatic economical consequences, and thus, public health policies
must be designed based on reliable predictions of the evolution of the pandemic to minimize
undesired effects on the global economy. For doing so, estimating the values of variables such
as the proportion of susceptible, infected and recovered individuals in the population, among
other variables, is of paramount importance. This is due to the fact that such variables are the
inputs of mathematical models that help to predict the evolution of the pandemic [1, 2], and
thus, impact public health policy-making. Reliable estimations of these variables can be achieved
in part by testing the population. Nonetheless, diagnosing SARS-CoV-2 is a challenging task
given that designing highly reliable tests for massive testing is still an open research problem,
c.f., [3, 4, 5].
In the general realm of epidemiology, the reliability of tests is measured in terms of two
parameters: sensitivity and specificity. The former is the probability with which a test is able
to correctly identify the presence of a condition, for example, a SARS-CoV-19 infection. Alter-
natively, the latter is the probability with which a test is able to correctly identify the absence
of such condition. Within this context, the main contribution of this work is a mathematical
formula for estimating the fraction of individuals that exhibit the condition in a population in
which every individual has been tested once with identical unreliable tests. In the following, this
fraction is referred to as the prevalence ratio [2]. In these terms, the main result is Theorem 1 in
Section 4, which presents an estimator of the prevalence ratio in terms of the sensitivity, speci-
ficity and the fraction of positive test results. More importantly, the estimation error induced
by such estimator is proved to decrease with the number of tests.
The novelty of this work with respect to existing methods for estimating the prevalence ratio,
for example, method of multipliers, capture and recapture methods, among others, c.f., [2, 6], is
that it takes into account the effects of both false positive and false negative probabilities. More
specifically, it takes into account the fact that some individuals that are infected could have been
declared noninfected and vice versa. This consideration has already been discussed by several
authors, c.f., [7, 8, 9, 10]. Nonetheless, a simple general formula for estimating prevalence ratios
in terms of the sensitivity, specificity, and the fraction of positive test results is not available
in current literature. This said, the prevalence ratio estimation presented in this work is based
exclusively on the results of data obtained through testing campaigns with unreliable binary
tests. No other assumption is taken into account. This breaks away from the studies based on
mathematical regressions in which some assumptions on the random variables are often adopted
and correctness is often the ground of vivid discussions, c.f., [11, 12, 13, 14]. In the particular
case of SARS-CoV-19, very little is known about the underlying stochastic properties of the virus
dissemination and thus, arbitrary assumptions might lead to estimation errors.
The main conclusions of this work are:
(i) The number of positive tests might be drastically different to the number of infected in-
dividuals in a population depending on the sensitivity and specificity of the tests. Hence,
the ratio between the number of positive tests and the total number of tested individuals
is not a reliable estimation of the prevalence ratio;
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(ii) Testing campaigns using tests for which the sum of the sensitivity and specificity is different
from one, always allow a reliable estimation of the number of infected individuals when a
sufficiently large number of individuals is tested in the population (Lemma 1 in Section 4);
(iii) Testing campaigns using a test for which the sum of the sensitivity and the specificity is
equal to one, lead to data from which it is impossible to estimate the prevalence ratio
independently of the number of tested individuals (Lemma 7 in Section 4); and
(iv) When the objective is to estimate the prevalence ratio in a population, the key parameter
for reducing the estimation error is the number of tests. That is, as long as the sum of
the sensitivity and specificity is different than one, and a large number of test results is
available, the exact values of both sensitivity and specificity have very little impact on the
estimation error.
The remaining sections of this paper are organized as follows: Section 2 presents a brief
overview of the tests for diagnosing SARS-CoV-2 and the reliability of the existing tests; Section 3
formulates the problem of estimating the prevalence ratio taking into account the sensitivity and
specificity of the tests; Section 4 presents an estimator of the prevalence ratio using data obtained
from unreliable tests, and the proofs of the main results; Section 5 introduces some examples
in which the impact of the sensitivity, specificity and number of tests on the estimation error is
numerically analyzed; Section 6 concludes this work.
2 Case Study: SARS-CoV-2
Tests for SARS-CoV-2 can be broadly divided into three groups: virological tests, serological
tests, and tests based on medical imaging. Each of these groups provide information about
different aspects of the infection and exhibit different reliability parameters.
2.1 Virological Tests
Virological tests inform about the presence of the SARS-CoV-2 virus genome in nasopharyngeal
(nasal swab) or oropharyngeal swabs (oral swab), blood, anal swab, urine, stool, and sputum
samples [15]. Individuals with positive virological tests are declared capable of contaminating
others, and thus, virological tests are central in decision-making and policy-making, c.f. [3, 5].
The reliability of virological tests in terms of sensitivity and specificity depends on a variety of
parameters. These parameters include the type of clinical specimen, the materials and methods
used for obtaining the specimens, specimen transportation, viral density of patients, and human
errors in data processing in laboratories. In the case of respiratory specimens, viral density
appears to play a central role in the sensitivity and specificity of virological tests, c.f., [16, 17].
This stems from the fact that during the first week after infection, the virus can be detected
by nasopharyngeal or oropharyngeal swabs. During the second week and later, the virus might
disappear in the upper parts of the respiratory system and migrate to the bronchial tube and the
lungs. From the studies in [16, 17], it appears that specimens from the lower respiratory track
increase the sensitivity and specificity of virological tests.
Virological tests are based on several techniques: (a) Reverse transcription polymerase chain
reaction (RT-PCR), c.f., [18, 19]; and (b) Reverse transcription loop-mediated isothermal ampli-
fication (RT-LAMP), c.f., [20, 21]; and (c) other techniques, c.f., [19, 22, 23].
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2.2 Serological Tests
Serological tests determine whether an individual has developed anti-bodies or antigens against
the SARS-CoV-2 virus. Nonetheless, an individual produces anti-bodies against SARS-CoV-2
only several days after contracting the infection. Typically, the time between infection and the
production of anti-bodies ranges from seven to fourteen days, c.f., [24, 25, 26]. Serological tests
are based on the enzyme linked immunosorbent assay (ELISA) and exhibit high specificity and
sensitivity, after fourteen days of infections [24]. This drastically limits the use of serological tests
in the early detection of the infection and policy-making, c.f., [3, 4]. In a nutshell, on the one
hand, a serological test answers the question whether an individual is or has been infected. On
the other hand, serological tests do not allow determining whether an individual has immunity
to the SARS-CoV-2 virus or whether the individual is currently spreading the virus. Up to the
day of publication of this paper, serological tests are not considered for massive testing in France,
c.f., [4].
2.3 Medical Imaging
Medical Imaging for detection of SARS-CoV-2 includes chest X-Ray and chest computed tomog-
raphy (CT) scans, which reveal ground-glass opacities and consolidations in the periphery of
the lungs of infected individuals [27]. Nonetheless, the sensitivity and specificity of CT depends
on the experience of radiologists to distinguish SARS-CoV-2 pneumonia from non-SARS-CoV-2
pneumonia [28]. In [29], it is reported that the sensitivity of CT is better than the one achieved
by RT-PCR tests.
3 Prevalence Ratio and Unreliable Tests
Consider a population subset of n individuals whose state is either susceptible (S) or infected (I)
and assume that all individuals of this population subset are tested with the same type of test.
Let the actual state of such n individuals be represented by the vector x ,
(
x1, x2, . . ., xn
)
.
That is, for all t ∈ {1, 2, . . . , n}, it follows that xt ∈ {I, S} is the true state of the individual t.
The result of testing individual t is denoted by yt ∈ {I, S}. Hence, the outcome of a testing
campaign over such population is a vector y ,
(
y1, y2, . . ., yn
)
∈ {I, S}n. Due to the fact that
tests possess strictly positive probabilities of false negatives and false positives, the vectors x
and y might be different. That is, some individuals that are infected could have been declared
susceptible and vice versa.
A central observation in this analysis is that a test for determining whether an individual is
contaminated by SARS-CoV-2 can be modeled by a random transformation PY |X for which the
input and output sets are {I, S}. More specifically, if an individual whose state is x ∈ {I, S} is
tested, the result y ∈ Y is observed with probability PY |X(y|x). Figure 1 shows this binary-input
binary-output model.
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Figure 1: A SARS-CoV-2 test represented by a random transformation from {I, S} into {I, S}
via the conditional probability distribution PY |X .
Using this notation, the sensitivity of the test is PY |X(I|I); and the specificity of the test is
PY |X(S|S). The probability of a false positive is PY |X(I|S) = 1−PY |X(S|S); and the probability
of a false negative is PY |X(S|I) = 1 − PY |X(I|I). This said, a test is fully described by any of
the following pairs of parameters:
• The sensitivity and the specificity;
• The sensitivity and the probability of a false positive;
• The probability of a false negative and the specificity; or
• The probability of a false negative and the probability of a false positive.
Let X be random variable taking values in {I, S} and denote by PX : {I, S} → [0, 1] its
probability distribution such that PX(I) is the actual fraction of infected individuals among
the n individuals. That is, PX(I) is the prevalence ratio of SARS-CoV-19 in this population
subset. For this reason, the probability distribution PX is referred to as the ground-truth input
probability distribution. Let Y be a second random variable taking values in {I, S} such that its
joint probability distribution with X is PXY and for all (x, y) ∈ {I, S}2,
PXY (x, y) = PX(x)PY |X(y|x), (1)
where the conditional distribution PY |X is the test. See, for instance, Figure 1. Often, the
probability distribution PY is referred to as the ground-truth output probability distribution and





The problem consists in using the data y obtained through a testing campaign with tests in
which parameters are modeled by PY |X to determine the fraction PX(I) of infected individuals
in the population, i.e., the prevalence ratio. More formally, the problem can be stated as follows:
Consider two random variables X and Y with the joint probability distribution PXY in (1). The
problem consists in estimating the probability distribution PX based only on n realizations y1,
y2, . . ., yn of the random variable Y , with n a finite integer. This problem is reminiscent to the
problem of population recovery introduced in [30] and further studied in [31, 32].
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4 Estimation of the Prevalence Ratio Using Unreliable Tests
Given the data y ∈ {I, S}n collected during a test campaign, the fraction of the population
reporting positive and negative tests form an empirical distribution denoted by P̄ (n)Y on the set

















where 1{·} is the indicator function. Essentially, P̄
(n)
Y is a counting probability measure for
which the values P̄ (n)Y (I) and P̄
(n)
Y (S) represent the fraction of positive and negative test results.
Hence, P̄ (n)Y (I) + P̄
(n)
Y (S) = 1. In the following, such probability measure is often referred to as
the output empirical distribution obtained from the data y.
Let P̂ (n)X : {I, S} → R be a function representing the estimation of PX based on the data y.
The error induced by estimating PX using P̂
(n)
X can be measured by the total variation, which
is denoted by
∥∥∥PX − P̂ (n)X ∥∥∥
TV





(∣∣∣PX(I)− P̂ (n)X (I)∣∣∣+ ∣∣∣PX(S)− P̂ (n)X (S)∣∣∣) (4)
=
∣∣∣PX(I)− P̂ (n)X (I)∣∣∣ . (5)
Note that in the case of binary tests, the total variation is simply the absolute difference




The following theorem presents the main result of this work.
Theorem 1. Consider a population of n individuals whose true ratio of infected (I) and suscep-
tible (S) individuals is PX(I) and PX(S) = 1−PX(S), respectively, with PX(I) ∈ [0, 1]. Assume
that all individuals of such population are tested with a test PY |X that satisfies
PY |X(S|S) + PY |X(I|I) 6= 1. (6)
Let P̄ (n)Y be the resulting output empirical probability distribution in (3) and assume that
P̄
(n)
Y (I) satisfies the following condition,
min{PY |X(I|I), PY |X(I|S)} 6 P̄
(n)
Y (I) 6 max{PY |X(I|I), PY |X(I|S)}. (7)




1− P̄ (n)Y (I)− PY |X(S|S)







Y (I)− PY |X(I|I)
1− PY |X(I|I)− PY |X(S|S)
, (8b)
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forms a probability measure that satisfies
lim
n→∞
∥∥∥PX − P̂ (n)X ∥∥∥
TV
= 0 in probability. (9)
In a nutshell, Theorem 1 states that the value P̂ (n)X (I) constitutes an estimation of the preva-
lence ratio PX(I). Moreover, it shows that such estimation is asymptotically optimal. That is,
approximating PX by P̂
(n)
X induces an error that vanishes when the number of tests n increases.
Nonetheless, despite the fact that P̂ (n)X (I) + P̂
(n)
X (S) = 1, it holds that for a small number of
tests n, P̂ (n)X (I) and P̂
(n)
X (S) do not necessarily form a probability measure. That is, it might
be observed that either P̂ (n)X (I) < 0 and P̂
(n)
X (S) > 1; or P̂
(n)
X (I) > 1 and P̂
(n)
X (S) < 0. Later,
in Lemma 4, it is shown that with a large number of test results, the fraction of positive results
P̄
(n)
Y (I) satisfies the inequalities in (7). Note also that the condition in (7) is necessary and suf-
ficient to observe that 0 6 P̂ (n)X (I) 6 1 in Theorem 1. This highlights the need for a sufficiently
large number of tests in order to obtain a valid estimation of PX(I) using Theorem 1.
Finally, note that the formulas in (8) are given in terms of the sensitivity PY |X(I|I) and
specificity PY |X(S|S) of the test. Nonetheless, it can be expressed in terms of the probabilities
of a false positive and a false negative, or any combination of the parameters describing the test.
The following corollary shows the formulas in (8) in terms of the probabilities of a false positive
PY |X(I|S) and a false negative PY |X(S|I).
Corollary 1. Consider a population of n individuals whose true ratio of infected (I) and suscep-
tible (S) individuals is PX(I) and PX(S) = 1−PX(S), respectively, with PX(I) ∈ [0, 1]. Assume
that all individuals of such population are tested with a test PY |X that satisfies (6). Let P̄
(n)
Y
be the resulting output empirical probability distribution in (3) and assume that P̄ (n)Y (I) satisfies






Y (I)− PY |X(I|S)





1− PY |X(S|I)− P̄
(n)
Y (I)
1− PY |X(S|I)− PY |X(I|S)
, (10b)
forms a probability measure that satisfies (9).
4.2 Proof of Theorem 1
The proof of Theorem 1 leverages the following intuition: Under the assumption that P̄ (n)Y ,
which is obtained from the data y as in (3), is a valid estimation of the ground-truth output












PY |X(I|I) PY |X(I|S)










is a good estimation of the input probability distribution PX . This intuition builds upon the
observation that the output distribution P̄ (n)Y induced by the data, must be the marginal of a
joint distribution consisting of the product of the conditional PY |X and the input distribution.
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which is equivalent to the system in (11).
With this intuition in mind, the proof proceeds as follows. First, it is shown that under the
condition in (6), there exists a unique pair (P̂ (n)X (I), P̂
(n)
X (S)) that satisfies the equality in (11).
This is essentially due to the fact that the equality in (11) forms a linear system of two equations
with two variables, and thus, if it is consistent, it has either a unique solution or infinitely many
solutions.
Lemma 1. Consider the empirical output distribution P̄ (n)Y in (3) obtained by a test described by
the conditional probability distribution PY |X . Then, the following five statements are equivalent:
• The system of equations in (11) has a unique solution;
• The sensitivity PY |X(I|I) and specificity PY |X(S|S) satisfy
PY |X(I|I) + PY |X(S|S) 6= 1; (12a)
• The sensitivity PY |X(I|I) and the probability of a false positive PY |X(I|S) satisfy
PY |X(I|I) 6= PY |X(I|S); and (12b)
• The probability of a false negative PY |X(S|I) and the specificity PY |X(S|S) satisfy
PY |X(S|S) 6= PY |X(S|I). (12c)
• The probability of a false positive PY |X(I|S) and the probability of a false negative PY |X(S|I)
satisfy
PY |X(I|S) + PY |X(S|I) 6= 1. (12d)
Proof. The proof of Lemma 1 follows from the fact that a unique solution to (11) is observed if
and only if the determinant of the matrixÅ
PY |X(I|I) PY |X(I|S)
PY |X(S|I) PY |X(S|S)
ã
is different from zero (Rouché–Fontené theorem [33]). That is,
PY |X(I|I)PY |X(S|S)− PY |X(S|I)PY |X(I|S) 6= 0. (13)
The proof is complete by verifying that the expression in (13) is equivalent to those in (12).
Note that all conditions in (12) are equivalent to each other, and thus, they are equivalent to
the condition in (6).
The proof of Theorem 1 continues by showing that when such a unique solution exists, it is
identical to the one shown in (8).
Lemma 2. Consider a test PY |X that satisfies at least one of the conditions in (12). Then,
under the assumption that the empirical output distribution P̄ (n)Y in (3) satisfies (7), the unique




1− P̄ (n)Y (I)− PY |X(S|S)







Y (I)− PY |X(I|I)
1− PY |X(I|I)− PY |X(S|S)
. (14b)
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Proof. The proof of Lemma 2 follows from solving the system of equations in (11) and observing
that P̂ (n)X is a probability measure if and only if condition (7) holds.
The rest of the proof of Theorem 1 consists of showing that the error vanishes with the
number of test results. This is shown in three steps. The first step consists of showing that
the total variation between PX and P̂
(n)
X , denoted by
∥∥∥PX − P̂ (n)X ∥∥∥
TV
, is equivalent to the total
variation between PY and P̄
(n)
Y , denoted by
∥∥∥PY − P̄ (n)Y ∥∥∥
TV
, up to a scaling factor.
Lemma 3. Consider a test PY |X that satisfies at least one of the conditions in (12). Then, under
the assumption that the empirical output distribution P̄ (n)Y in (3) satisfies (7), the estimation P̂
(n)
X
in (8) of PX satisfies∥∥∥PX − P̂ (n)X ∥∥∥
TV
=
1∣∣1− PY |X(I|I)− PY |X(S|S)∣∣
∥∥∥PY − P̄ (n)Y ∥∥∥
TV
, (15)
where PX and PY are the input and output probability distributions in (1) and (2), respectively.
Proof. The proof of Lemma 3 follows from the definition of total variation in (4) and from
equalities in (14).
Note that Lemma 3 proves the intuition over which the proof of Theorem 1 is based on.
That is, if P̄ (n)Y is sufficiently close to PY , then P̂
(n)
X must be sufficiently close to PX . The
following lemma shows that the more test results are available, the closer P̄ (n)Y and PY are in
total variation.
Lemma 4. Consider a test PY |X that satisfies at least one of the conditions in (12). Then, the
empirical output distribution P̄ (n)Y in (3) satisfies
lim
n→∞
∥∥∥PY − P̄ (n)Y ∥∥∥
TV
= 0 in probability, (16)
where PY is the ground-truth output probability distribution in (2).
Proof. The proof of Lemma 4 is a consequence of the Theorem of Glivenko and Cantelli [34].
Finally, from Lemma 3 and Lemma 4, it holds that by increasing the number of tests, the
error of approximating PX by P̂
(n)
X in (14) can be made arbitrarily small. The following lemma
leverages this observation.
Lemma 5. Consider a test PY |X that satisfies at least one of the conditions in (12). Then,
under the assumption that the empirical output distribution P̄ (n)Y in (3) satisfies (7), the input
distribution PX and the estimation P̂
(n)
X in (8) satisfy
lim
n→∞
∥∥∥PX − P̂ (n)X ∥∥∥
TV
= 0 in probability. (17)
Proof. The proof of Lemma 5 is an immediate consequence of both Lemma 3 and Lemma 4.
This completes the proof of Theorem 1.
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4.3 Connections to Maximum Likelihood Estimation
In this section, it is shown that the estimator presented in Theorem 1 is also the maximum
likelihood estimator. For doing so, note that under the assumption that the prevalence ratio
is P̂ (n)X (I) ∈ [0, 1], the probability of observing y ∈ {I, S}, as the result of testing any of the










From this perspective, the probability of observing the vector y = (y1, y2, . . . , yn), as the
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where P̄ (n)Y and P̂
(n)
Y are defined in (3) and (18), respectively. Hence, the log-likelihood function
L : {I, S}n × [0, 1]→ [0, 1] is for all y ∈ {I, S}n and P̂ (n)X (I) ∈ [0, 1],
L(y, P̂
(n)





































































































denotes the Kullback–Leibler divergence between the distributions P̄ (n)Y and P̂
(n)









> 0, it follows that
L(y, P̂
(n)















= 0. That is, when both P̄ (n)Y and P̂
(n)
Y are
identical. This observation leads to the conclusion that the log-likelihood function is maximized
when the assumed prevalence ratio P̂ (n)X (I) is such that P̄
(n)
Y in (3) and P̂
(n)
Y in (18) are identical,
which is induces the system of equations in (11) and in which the unique solution is formed by
the equalities in (8). This proves that the estimator in Theorem (1) is the unique maximum
likelihood estimator.
5 Final Remarks
This section highlights some of the conclusions drawn from Lemma 1–5 using a numerical analysis
in particular examples. In the following examples, the data is artificially generated. That is,
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Figure 2: Relation between the input vector x = (x1, x2, . . . , xn) ∈ {I, S}n (state of the individ-
uals); the output vector y = (y1, y2, . . . , yn) ∈ {I, S}n (result of the tests); the calculation of the
fraction of positive tests P̄ (n)Y (I) in (3); and estimation of the prevalence ratio P̂
(n)
X (I) in (8a).
for a given prevalence ratio PX(I), an n-dimensional vector x =
(
x1, x2, . . ., xn
)
∈ {I, S}n is
generated such that for all t ∈ {1, 2, . . . , n}, xt is a realization of a random variable X ∼ PX
and represents the state of individual t. Given a test PY |X , an n-dimensional vector y =
(
y1,
y2, . . ., yn
)
∈ {I, S}n is generated such that for all t ∈ {1, 2, . . . , n}, yt is the realization of a
random variable Yt ∼ PY |X=xt and represents the result of the test of individual t. Using the
vector y, the fraction of positive tests P̄ (n)Y (I) is calculated using (3); and the estimation P̂
(n)
X (I)
of the prevalence ratio PX(I) is calculated using (8a). Figure 2 shows this procedure. From this
perspective, the analysis is based on simulated testing campaigns. Note that the use of simulated
data allows knowing the actual prevalence ratio, which enables analyzing the estimation error.
This is rarely possible with data from actual testing campaigns.
Example 1. Consider a population of n = 10, 000 individuals with prevalence PX(I) = 0.4.
Assume that all individuals are tested with identical tests PY |X .
Example 2. Consider a population of n = 100, 000 individuals with prevalence PX(I) = 0.4.
Assume that all individuals are tested with identical tests PY |X .
Example 3. Consider a population of n = 100, 000, 000 individuals with prevalence PX(I) = 0.4.
Assume that all individuals are tested with identical tests PY |X .
In Figure 3–8, the actual prevalence ratio PX(I) is plotted with a straight black line; the
estimation P̂ (n)X of PX is plotted with red circles; the fraction of positive tests P̄
(n)
Y (I) is plotted
with blue diamonds; and the value of PY (I) in (2) is plotted with a dashed red line. In Figures 3,
5 and 7, these values are plotted as a function of the specificity PY |X(S|S) for a fixed sensitivity.
Alternatively, in Figures 4, 6 and 8, these values are plotted as a function of the sensitivity
PY |X(I|I) for a fixed specificity. For each of the examples, one vector x ∈ {I, S}n is generated.
In all figures, Figure 3–8, each plotted point of P̄ (n)Y (I) (blue diamonds) and P̂
(n)
X (I) (red circles) is
calculated using a single vector y generated by the same vector x, according to the corresponding
values of sensitivity PY |X(I|I) and specificity PY |X(S|S), as described above. In the following
sections, some remarks based on these examples are presented.
5.1 Relevance of the Sensitivity and Specificity
One of the main observations to be highlighted from this numerical analysis is that there exists
an important difference between the fraction of positive tests P̄ (n)Y (I) and the actual prevalence
ratio PX(I) due to the sensitivity and specificity of the tests. This difference is clearly depicted
in Figure 3–8, which together with the mathematical analysis presented before, highlights the
conclusion that the fraction of positive tests should not be used as an estimation of the prevalence
ratio in public health policy-making.
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The following lemma determines the influence of the sensitivity and specificity on P̄ (n)Y (I).
For doing so, note that from Lemma (2), it holds that the fraction of individuals reporting
positive tests P̄ (n)Y (I) satisfies:
P̄
(n)
Y (I) = 1− PY |X(S|S)
Ä









Lemma 6. Consider a test PY |X that satisfies at least one of the conditions in (12). Then, given
the empirical output distribution P̄ (n)Y in (3) and assuming that it satisfies (7), the following
statements hold:
• The fraction P̄ (n)Y (I) of positive tests linearly decreases with the specificity of the test
PY |X(S|S);
• The fraction P̄ (n)Y (I) of positive tests linearly increases with the probability of a false positive
of the test PY |X(I|S);
• The fraction P̄ (n)Y (I) of positive tests linearly increases with the sensitivity of the test
PY |X(I|I); and
• The fraction P̄ (n)Y (I) of positive tests linearly decreases with the probability of a false neg-
ative of the test PY |X(S|I).
Proof. The proof of Lemma 6 consists in verifying that the derivative of P̄ (n)Y in (26) with respect
to PY |X(S|S) is negative; with respect to PY |X(I|S) is positive; with respect to PY |X(I|I) is
positive; and with respect to PY |X(S|I) is negative.
The statements in Lemma 6 become evident in Figures 3, 5 and 7. In these figures, it is
shown that the fraction of positive tests increases with the sensitivity; where as in Figure 4, 6
and 8, it is shown that the fraction of positive tests decreases with the specificity, c.f., Lemma 6.
From this perspective, tests might lead to countings in which the fraction of individuals reporting
positive testing results P̄ (n)Y (I) is bigger than the actual prevalence ratio PX(I), i.e., P̄
(n)
Y (I) >
PX(I). Alternatively, tests might also lead to estimations in which the fraction of individuals
reporting positive testing results P̄ (n)Y (I) is smaller than the actual prevalence ratio PX(I), i.e.,
P̄
(n)
Y (I) < PX(I). These observations highlight the relevance of using the estimation P̂
(n)
X of PX
for decision and policy making instead of P̄ (n)Y , which includes false positives and false negatives.
5.2 Tests whose Results are Useless
In Figure 3–8, the value of the sensitivity PY |X(I|I) and specificity PY |X(S|S) that satisfy
PY |X(I|I) + PY |X(S|S) = 1 are plotted with a blue dash-dot vertical line. Note that for these
specific values of sensitivity and specificity, the estimation P̂ (n)X (I) of PX(I) is not plotted. The
following lemmas shed some light into this singularity.
Lemma 7. Consider the empirical output distribution P̄ (n)Y in (3) obtained by a test described by
the conditional probability distribution PY |X . Then, the following five statements are equivalent:
• The system of equations in (11) has infinitely many solutions;
RR n° 9344
On the true number of COVID-19 infections 16
• The sensitivity PY |X(I|I) and specificity PY |X(S|S) satisfy
PY |X(I|I) + PY |X(S|S) = 1; (27a)
• The sensitivity PY |X(I|I) and the probability of a false positive PY |X(I|S) satisfy
PY |X(I|I) = PY |X(I|S); (27b)
• The probability of a false negative PY |X(S|I) and the specificity PY |X(S|S) satisfy
PY |X(S|S) = PY |X(S|I); and (27c)
• The probability of a false positive PY |X(I|S) and the probability of a false negative PY |X(S|I)
satisfy
PY |X(I|S) + PY |X(S|I) = 1. (27d)
Proof. The proof of Lemma 7 follows from the theorem of Rouché and Fontené [33] that states
that when the system in (11) is consistent, it has infinitely many solutions if the determinant of
the matrix Å
PY |X(I|I) PY |X(I|S)
PY |X(S|I) PY |X(S|S)
ã
is not full rank. When such a matrix is not full rank, its determinant is zero. That is,
PY |X(I|I)PY |X(S|S)− PY |X(S|I)PY |X(I|S) = 0. (28)
The proof is completed by verifying that the expression in (28) is equivalent to those in
(27).
When at least one of the equalities in (27) is satisfied, nothing meaningful can be said about
PX based on the data. This is essentially because any probability distribution P̂
(n)
X satisfies the
equality in (11). The following lemma reinforces this statement in terms of information measures.
Lemma 8. Consider a test PY |X that satisfies at least one of the conditions in (27). Hence, the
following statements are equivalent:
• Given the output empirical distribution P̄ (n)Y obtained from the data y as in (3), any prob-
ability distribution P̂ (n)X on {I, S} satisfies the equality in (11);
• Two random variables X and Y , in which the joint probability distribution PXY satisfies
(1), have zero mutual information; and
• Two random variables X and Y , in which the joint probability distribution PXY satisfies
(1), are independent.
Proof. The first statement is a consequence of Lemma 7; the second statement follows from the













where PX , PY |X , and PY satisfy the equality in (1). The third statement follows from the fact
that two random variables are independent if and only if their mutual information is zero.
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Lemma 8 shows that when at least one of the conditions in (27) holds, the output probability
distribution PY does not provide any information about the input probability distribution PX .
That is, nothing can be said about PX based on the data y.
Despite the singularity, the values of specificity and sensitivity in which the sum is close to
one, i.e., around the singularity, are also worthy of discussion. Note that for some 1 > ε > 0,
the absolute difference
∣∣∣PX(I)− P̂ (n)X (I)∣∣∣ is bigger when the sensibility and specificity satisfy∣∣1− PY |X(S|S)− PY |X(I|I)∣∣ < ε than when these parameters satisfy ∣∣1− PY |X(S|S)− PY |X(I|I)∣∣ >
ε. These observations are justified by the fact that the total variation




∥∥∥PY − P̄ (n)Y ∥∥∥
TV
up to a constant factor, as shown in Lemma 3. Such a factor is indeed
1
|1−PY |X(I|I)−PY |X(S|S)| , and thus, larger errors are expected around the singularity for the same
finite numbers of tests n. This is evident in the numerical analysis. In Example 1, i.e., Fig-
ures 3 and 4, around the singularity, the estimations P̂ (n)X of PX appear more disperse than the
estimations in Example 3, i.e., Figures 7 and 8.
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(a) Specificity is 39.6 %












(b) Specificity is 70.8 %
Figure 3: Population in which the fraction of individuals infected with SARS-CoV-2 is PX = 0.4
and n = 10, 000 individuals are tested (Example 1).
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(a) Sensitivity is 29.2 %












(b) Sensitivity is 70.8 %
Figure 4: Population in which the fraction of individuals infected with SARS-CoV-2 is PX = 0.4
and n = 10, 000 individuals are tested (Example 1).
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(a) Specificity is 39.6 %












(b) Specificity is 70.8 %
Figure 5: Population in which the fraction of individuals infected with SARS-CoV-2 is PX = 0.4
and n = 100, 000 individuals are tested (Example 2).
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(a) Sensitivity is 29.2 %












(b) Sensitivity is 70.8 %
Figure 6: Population in which the fraction of individuals infected with SARS-CoV-2 is PX = 0.4
and n = 100, 000 individuals are tested (Example 2).
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(a) Specificity is 39.6 %












(b) Specificity is 70.8 %
Figure 7: Population in which the fraction of individuals infected with SARS-CoV-2 is PX = 0.4
and n = 100, 000, 000 individuals are tested (Example 3).
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(a) Sensitivity is 29.2 %












(b) Sensitivity is 70.8 %
Figure 8: Population in which the fraction of individuals infected with SARS-CoV-2 is PX = 0.4
and n = 100, 000, 000 individuals are tested (Example 3).
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5.3 Impact of the Number of Tests.
Figure 3–8 show that when the parameters of the test satisfy at least one of the conditions in
(12) and there exist a sufficiently large number of test results, it is always possible to obtain
an estimation P̂ (n)X (I) of the prevalence ratio PX(I). This is independent of the exact values
of the specificity and sensitivity as long as (12) holds. More importantly, the reliability of such
estimation increases with the number of test results. For instance, compare the estimations in
Examples 1 and 3. The implications of this observation are very important in practical terms.
This shows that if the objective of a testing campaign against SARS-CoV-2 is to determine the
prevalence ratio, the quality of the tests is not important. This is essentially because testing with
low quality tests (low sensitivity and low specificity) or high quality tests (high sensitivity and
high specificity) leads to identical results in terms of the estimation error, when a large number of
tests is performed. Nonetheless, when a low number of tests is available, it is worth noting that
when the sensitivity PY |X(I|I) and specificity PY |X(S|S) satisfy
∣∣1− PY |X(S|S)− PY |X(I|I)∣∣ >
1− ε, for some 0 < ε < 1, the smaller ε, the smaller the estimation error of the prevalence ratio,
c.f., Lemma 3. This observation is of paramount importance as it implies that smaller estimation
errors are observed when the sum of the sensitivity and specificity is bounded away from one.
This said, the key parameter for reducing the estimation error is the number of tests.
6 Conclusions
In this work, it has been shown that estimating the prevalence ratio of a condition, for example,
a SARS-CoV-19 infection, by the ratio between the number of positive test results and the total
number of tests leads to excessive estimation errors when tests are unreliable. This is simply
due to the fact that unreliable tests, i.e., tests in which probabilities of false positives and false
negatives are nonzero, lead to some individuals exhibiting the condition to observe negative
test results (false negatives), and some individuals who do not exhibit the condition to observe
positive results (false positives). From this perspective, an estimation of the prevalence ratio
using data obtained from tests must take into account both the sensitivity and the specificity
of the tests. Theorem 1 provides an estimation of the prevalence ratio with an estimation error
that decreases with the number of tests.
Another important conclusion of this work is that testing campaigns using tests for which the
sum of the sensitivity and specificity is different from one, always allow a reliable estimation of
the prevalence ratio (Lemma 1 in Section 4) subject to a sufficiently large number of individuals
being tested. Alternatively, testing campaigns using tests for which the sum of the sensitivity and
the specificity is equal to one, lead to data from which it is impossible to estimate the prevalence
ratio even with infinitely many tests (Lemma 7 in Section 4).
A final conclusion is that for estimating the prevalence ratio of a given condition, i.e., a SARS-
CoV-2 infection, the key parameter for reducing the estimation error is the number of tests.
Surprisingly, as long as the sum of the sensitivity and specificity of the tests is different than
one, the exact values of both sensitivity and specificity have very little impact in the estimation
when the number of tests is sufficiently large.
7 Further Research
The results presented in this work exhibit many limitations and thus, further research is needed to
relax certain assumptions that might not be necessarily realistic. The following sections describe
several research paths in this direction.
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7.1 Beyond Binary Tests
This work has been developed considering that tests can exclusively distinguish between infected
and susceptible individuals. That is, the input and the output of the random transformation
PY |X in (1) are binary. Nonetheless, with the advancement on the knowledge about the SARS-
CoV-2, in the near future, it would be possible to distinguish more states, e.g., immune; infected
and contagious; infected and noncontagious; among others. This extension is trivial as long as
the matrix it induces in the system in (11) is invertible. The matrix is not invertible when an
additional state is considered, e.g., undetermined. The state undetermined can be a state in
which the test is not capable of classifying the individual among the input states, and thus, a
new state is considered at the output. The mathematical model would be far from trivial and
reminiscent to that of population recovery with lossy observations [35].
7.2 Tests with Unknown Parameters
One of the assumptions adopted for developing the results of this report is that the sensitivity
and the specificity of the tests are assumed to be known. Nonetheless, despite the data obtained
from the provider of the tests, the method and preparation of the staff responsible of taking the
samples, as well as, the manipulation and transportation of samples, play a central role in the
final sensitivity and specificity of the tests. From this perspective, formulating the problem in
which the random transformation PY |X in (1) is not completely known is an important research
direction.
7.3 Non-Independent Tests
The results obtained in this work rely on the assumption that the testing results obtained by each
individual are independent of all other individuals. This assumption neglects obvious interactions
between individual, e.g., members of the same family. An important research direction is the
case in which such interactions are taken into account and thus, correlations between the input
random variables are considered. This would allow to consider the existence of clusters among the
population and thus, refine the estimation of the number of infected individuals in the population.
7.4 Finite Number of Tests and Budget Optimization
An essential constraint that has been neglected in this study is the cost of performing a test.
Hence, a relevant questions is: given a number a number tests n and the knowledge of the existing
interactions among the individuals, what are the n individuals that must be tested to reduce
the estimation error of the number of infected individuals. In this direction, the consideration
of the correlation between the state of each individual is essential, which leads to a nontrivial
mathematical problem in which elements of group testing [36] might play an essential role.
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